DX-2930 Phase 1a Data Review Burt Adelman, MD Yung Chyung, MD Chris Tenhoor, PhD

First Page		Document Content
Blood Biology Complement deficiency Prekallikrein C1-inhibitor Kallikrein Coagulation Hereditary angioedema Ecallantide Kinin system Blood proteins Coagulation system		DX-2930 Phase 1a Data Review Burt Adelman, MD Yung Chyung, MD Chris Tenhoor, PhD Add to Reading List Source URL: files.shareholder.com Download Document from Source Website File Size: 1,16 MB Share Document on Facebook

	[Product Monograph Template - Schedule D] DocID: 1qWQL - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1qHpD - View Document
	Microsoft Word - CINRYZE.Product Monographdoc DocID: 1qE2h - View Document
	Microsoft Word - FIRAZYR.Product Monographdoc DocID: 1qA9x - View Document
	Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop DocID: 1pVHk - View Document